OPPORTUNITIES THROUGH ORACLE'S RELSYS ACQUISITION
On March 23, 2009, Oracle announced it agreed to acquire Relsys, a leading provider of drug safety, risk management and analytics applications for the health sciences industry. Relsys's best-in-class solutions support adverse event reporting, risk management and drug safety analysis for pharmaceutical, biotechnology, contract research organizations and medical device companies worldwide.
The combination of Relsys and Oracle's Health Sciences industry suite of products is expected to deliver the only suite of software applications that supports the end-to-end drug safety processes across clinical development, post-market surveillance and patient care.
Customers are expected to be able to identify safety issues earlier in the development process which can significantly reduce the costs associated with bringing drugs and devices to market. In addition, customers are expected to experience better insight and visibility across safety processes through an integrated and comprehensive view of data across adverse events, clinical studies and observational data.